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Purpose/Objective: To evaluate the relevance of rotational shift in 
IGRT prostate RapidArc and to validate the added value of Protura 6 
degree of freedom (DOF) Robotic Patient Positioning System (CIVCO 
Medical Solution) to improve setup accuracy with the Cone Beam CT 
scanner (CBCT). 
 Materials and Methods: We enrolled patients with cT3aN0M0 low risk 
for nodal involvement prostate cancer. RapidArc simultaneous 
integrated boost treatment plans were made; a total dose of 80Gy 
(200cGy/ fraction) to prostate and 72Gy (180cGy/fraction) to the 
seminal vesicle base were delivered. Patients in supine position with 
dual leg immobilization (CIVCO support system) underwent to 
simulation a computerized tomography (CT) scan for radiotherapy 
planning. A CBCT was performed daily before dose delivery. Images 
were then compared with the simulation CT images in order to 
determine the magnitude of set-up error and organ motion. 
Translational (Lateral, Vertical and Longitudinal) and Rotational 
(Pitch, Yaw and Roll) shifts were identified with manual and/or 
automatic 3D matching (Varian 6D Online Review System). The 
collected shifts were applied on the Protura Robotic Patient 
Positioning System to obtain a more accurate alignment. Mean 
translation and rotation shifts were calculated. The 3D-vector of 
displacement was also worked out and the total procedure time was 
recorded. 
Results: From October to December 2012, we enrolled 5 patients with 
a median age of 76 yrs (range 64-78). One hundred and thirty-two 
CBCT studies were performed and compared to CT images. The mean 
(±SD) interfraction displacement in vertical, lateral and longitudinal 
direction was -0.2 ± 0.3 cm, 0.0 ± 0.3 cm and -0.2 ± 0.5 cm 
respectively. The maximal translation setup shift was 1.4 cm 
vertically, 1.6 cm longitudinally and 1 cm laterally, with 98% of the 
shifts < 1 cm. The mean (±SD) 3D vector of displacement was 0.3 ± 0.7 
cm. The mean (±SD) interfraction rotations were: Pitch= -0.4 ± 1.1°, 
Roll= -0.5 ± 1.2° and Yaw= 0.1 ± 0.7°. The maximal rotation error was 
2.8° for Pitch, 3.8° for Roll and 2.1° for Yaw, with 91% of the 
rotations < 2°. No correlation was observed between the magnitude of 
translational and rotational shift. The mean time for all treatment 
procedures was 14.52 ± 2.02 minutes. Despite the manual transfer of 
data to the Protura software in this phase, no more than one extra 
minute was required compared to the standard procedure. 
Conclusions: Our preliminary data shows that the Protura Robotic 
Patient Positioning System is essential to improve accuracy in the 
IGRT era. It underlines the necessity to perform rotational shifts, 
especially in prostate treatments. Correlation between volumetric and 
geometrical shift data and evaluation of its dosimetrical impact on 
adaptive dose is ongoing. 
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Purpose/Objective: To analyse inter-fractional prostate bed motion 
(PBM) and to quantify its components using an endorectal balloon 
(ERB) and daily cone beam computed tomography (CBCT). 
Materials and Methods: A total of 1,348 CBCT images from 46 patients 
who underwent postprostatectomy radiotherapy were analysed. Total 
set-up error was defined as the shift from the skin mark to the 
prostate bed matching, based on anterior rectal wall stretching by the 
ERB. Prostate bed motion (PBM) was defined as the difference 
between the total set-up error and bony misalignment (BM).  
Results: The systematic errors for the total set-up error were 1.0, 
1.3, and 1.0 mm in the right-left, anterior-posterior, and superior-
inferior directions, respectively, with random errors of 1.9, 2.4, and 
1.9 mm, respectively. Systematic errors were 1.6, 1.6, and 0.3 mm for 
BM and 0.8, 1.1, and 0.9 mm for PBM, with random errors of 2.4, 2.5, 
and 1.1 mm for BM and 1.8, 2.2, and 1.9 mm for PBM. 
Conclusions: Planning target volume margins of <5 mm were needed 
to include 95% of the inter-fractional variations when using an ERB. 
The BM was the main component of the total set-up error, which 
indicated that inter-fractional PBM was well controlled by the ERB. 
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Purpose/Objective: Whole-pelvis radiotherapy (WPRT) may have a 
role in post-prostatectomy (POSTOP), both adjuvant (ADV) and salvage 
(SALV) radiotherapy (RT) after radical prostatectomy for prostate 
cancer (PCa). Haematological toxicity (HT) from WPRT for PCa has 
never been evaluated. Moreover, HT from WPRT has thus far been 
analyzed only in patients treated with concurrent chemoradiation. A 
prospective evaluation of HT in PCa patients receiving postoperative 
WPRT was therefore activated.  
Materials and Methods: From November 2011 to October 2012, 50 
consecutive patients receiving WPRT as a part of ADV (n=29) or SALV 
(n=21) POSTOP RT were analyzed. The collection of a complete blood 
sample before RT start (baseline), at RT mid-point, at RT end, at 90 
days from RT completion and subsequently every six months for 3 
years was planned. This first analysis is aimed at quantifying early 
blood cell changes on the first 50 patients with complete baseline, 
mid-point and end RT data; for 25/50, data at 90 days were also 
available. Patients were treated with conventionally fractionated (CF, 
1.80 Gy/fraction, n=16) or moderately hypofractionated (HYPO, 2.35-
2.60 Gy/fr, median 2.35, n=34) RT, with IMRT (n=13), Volumetric Arc 
(VMAT, n=31) or Helical Tomotherapy (n=6) technique. For CF and 
HYPO, RT dose to the prostatic bed ranged from 72 to 77.4 Gy and 
from 65.8 to 72.8 Gy, respectively, while WPRT dose was 50.4 and 
51.8 Gy, respectively. Mean and median values of white (WBC) and 
red blood cells (RBC), platelets (PLT) and haemoglobin (Hb) were 
calculated for each time point. Significant differences against the 
baseline were assessed by the Mann-Whitney test. Difference between 
the nadir value and the last available value was also tested. 
Results: Results are summarized in Figure 1. Median WBC count at RT 
mid-point and at RT end were 67% and 68% of the baseline, 
respectively. The corresponding values for RBC, PLT and Hb were: 97% 
and 95% for RBC, 89% and 101% for PLT, and 97% and 95% for Hb. When 
focusing on WBC subpopulations, the acute HT was found to be more 
significant: the corresponding median absolute neutrophil and 
lymphocyte counts (ANC and ALC, respectively) were, in fact, 73% and 
80% for ANC, and 38% and 31% for ALC, respectively. For patients with 
data available at 90 days from RT end, the WBC, RBC, PLT, Hb, ANC 
and ALC median values were 73%, 93%, 107%, 97%, 86% and 44% of the 
corresponding baseline. The differences between the nadir and the 
basal value was significant (p≤0.0016) for all parameters except PLT. 
The last available value (end RT or 90 days) was significantly 
increased relative to the nadir value for ALC only (p<0.0001). 
  
Conclusions: A significant blood count reduction, particularly 
significant for ALC, occurs during and immediately after post-
prostatectomy WPRT. Future analyses will focus on the long-term 
recovery of HT on a much larger population as well as on the 
assessment of dosimetry and clinical predictors of HT.  
   
PO-0729   
Development of late toxicity treated with image-guided volumetric 
modulated arc therapy for prostate cancer. 
K. Yamamoto1, K. Shiraishi1, A. Nomoto1, A. Haga1, A. Sakumi1, K. 
Nakagawa1 
1Tokyo Univ. Hosp. Radiology, Radiology, Tokyo, Japan  
 
Purpose/Objective: To evaluate the genitourinary toxicity and 
chronological changes of the International Prostate Symptom Score 
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(IPSS) in prostate cancer patients who received image-guided 
volumetric modulated arc therapy (IG-VMAT). 
Materials and Methods: From August 2008 to November 2011, 190 
consecutive prostate cancer patients were treated with IG-VMAT to a 
dose of 76 Gy with daily correction of the target position based on 
cone-beam CT imaging. The IPSS and Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.0 toxicity were prospectively 
scored before VMAT, at the end of VMAT, 1, 3, 6, 12, 18, 24 and 36 
months after VMAT. IPSS resolution was defined as a return to within 1 
point of the score at baseline. Clinical, treatment-related parameters 
were evaluated included patient age, alpha-blocker use, androgen 
deprivation therapy (ADT) use, body mass index, diabetes, 
hypertension, smoking and drinking habits, and prostate volume. 
Dosimetric quality indicators were also examined. 
Results: The median follow-up was 24.2 months (range,11.3-47.6). 
134 (70.5%) patients took ADT medications. At last follow-up, 67 
(35.3%) patients took alpha-blocker medications. The 2-year actuarial 
rate of grade 2 or greater genitourinary toxicity was 2.6%. The median 
(inter-quartile range) IPSS before VMAT, at the end of VMAT, 1, 3 
months after VMAT and at last follow-up were 3(1-7), 9(5-12), 6(2-9), 
3(1-8), and 4(1-7), respectively. The IPSS returned to baseline at a 
median of 3.0 months. The IPSS of 49 patients (25.8%) didn't exceed 
baseline+2 throughout the follow up. In Cox regression analysis, only 
drinking habit was associated with increased IPSS exceed baseline+2 
(95% CI 0.283-0.907, p=0.022). 
Conclusions: In IG-VMAT, IPSS resolved within 3 months substantially, 
and late GU toxicity was very low. Cessation of drinking during 
radiotherapy may be useful for further improvement. 
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Purpose/Objective: Most researchers consider kidney cancer 
radioresistant and in light of this what seems to be the 'common 
knowledge' use of radiation therapy to treat those lesions is not 
effective. An analysis of traditional approach indicate the possibility 
of changing that dogma, aiming to of achieve positive results in the 
implementation of radiosurgical abilities to deliver ablative radiation 
doses by means of radiosurgical system CyberKnife. 
Materials and Methods: Fifty patients with medically inoperable renal 
cell cancer (RCC), (from October 2009 to December 2012) were 
treated with robotic SBRT CyberKnife modalities. Eighteen (18) of 
them were diagnosed with single kidney (RCC). All 18 patients had 
metastases from malignant kidney to contralateral kidney and three of 
them had metastases spread to brain, lung, and pancreas. 
Dose/fractionation schedules varied between 10 to 13 Gy per 
fractionand 3 to 4 sessions on kidney and 15 to 20 Gy, 1 to 3 sessions 
on other metastases depending on target location, and size. Tumor 
volume varied from 5 to 180 cc. Follow-up times for patients who 
remained alive were 6 to 25 months and for those who died 
(2patients) were 14 to17 months. 
Results: All eighteen patients were carefully followed by 
multidisciplinary team, contrasted CT scans, renal scintigraphy, and 
blood work was analyzed. Local controls defined as radiologically 
stable disease or partial/complete response was obtained in all 
eighteen patients with single kidney. A partial response as defined as 
a greater than 50% reductions tumor volume was noted in 12 patients. 
Kidney function remained unaffected after treatment in seventeen 
patients, the Creatinine levels remained normal, but one (slightly 
elevated up to 125 mmol/L). Parameters of the dynamic renal 
scintigraphy not affected by the radiosurgery. Side effects were mild, 
grade 1 in 8 cases. No patient was reported with grade 2 to 4 toxicity. 
No complications of the fiducial placement reported. 
Conclusions: The results show positive effect of treatment. These can 
be evaluated as an alternative to surgery and provide local control 
while maintaining the function of a single kidney. Stereotactic body 
radiationtherapy (SBRT), also known as stereotactic ablative 
radiotherapy (SABR), is emerging as one of the new treatment options 
for renal cell cancer (RCC) mainly in medically inoperable patients 
especially reducing surgical risks in patients with single remaining 
kidney.  
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Purpose/Objective: Dose escalation is known to improve outcomes in 
prostate cancer at the expense of a higher risk of side effects. Focal 
dose escalation, targeting the area most at risk of recurrence, may 
improve outcomes without increasing the burden of toxicity, 
especially as the majority of intra-prostatic recurrence occurs at the 
site of the dominant disease nodule at presentation. Fast dose fall-off 
with new radiotherapy techniques such as Cyberknife and Rapid Arc 
improves our ability to dose paint. 
Materials and Methods: Fifteen patients, who were previously treated 
with IMRT at our institution, and had dominant intra-prostatic disease 
nodules (DPDN) on MRI were selected. Their diagnostic MRI was fused 
with their radiotherapy planning CT and the DPDN was contoured with 
the assistance of an expert radiologist. For RapidArc plans, two PTV 
margins were employed: Cyberknife margins (5mm expansion of the 
prostate, except 3mm posteriorly) and larger margins (prostate + 
8mm/4mm posteriorly) in order to account for intra-fraction motion. 
Trial plans were constructed in order to deliver 36.25 Gy in 5 fractions 
to the PTV (as defined above) with a simultaneous integrated boost 
(SIB) of 47.5 Gy to the DPDN which was planned with no PTV margin. 
Minor relaxation of our usual SBRT dose constraints were allowed to 
facilitate the boost dose, as long as the plan was deemed clinically 
acceptable.  
Results: With 5/3mm margins, RapidArc and Multiplan wereboth able 
to produce SIB plans within constraints in most patients. Mean rectal 
D50% and D20% doses were lower for RapidArc compared with 
Multiplan (p=0.01 and 0.005 respectively) but the constraints were 
exceeded in approximately the same number of occasions. If the PTV 
(8/4mm) margin was increased, over half the tolerances were 
exceeded. 
 
Conclusions: Both RapidArc and Multiplan can produce clinically 
acceptable SIB plans, focally escalating to 47.5 Gy, within standard 
OAR constraints. However, if a margin large enough to account for 
intra-fraction motion is used, the RapidArc plans no longer meet the 
required dose constraints. Focal SIB treatments are feasible if intra-
fraction motion can be tracked and corrected.  
 
 POSTER: CLINICAL TRACK: GYNAECOLOGICAL 
TUMOURS  
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Purpose/Objective: To evaluate a toxicity and efficacy of carbon ion 
radiotherapy for gynecological melanoma, we conducted a Phase I/II 
clinical trial. 
Materials and Methods: The eligibilitycriteria for enrollment in this 
study were (1) histologically proven malignantmelanoma, (2) a 
localized measurable tumor in gynecological region, (3) atleast a 5 
mm gap between the tumor and radiosensitive organs, including bowel 
and bladder, and (4) a expected prognosis of more than 6 months. 
Tumors were classifiedby TNM classification for malignant melanoma. 
In principle, tumors with PTV margins were irradiated 3.6 GyE per 
fraction up to the total dose of 57.6 GyE in 16 fractions, 4 times a 
week. Acute toxicities were assessed according to NCI-CTCAE ver.4.0 
within 3 months after the treatment. Treatment response was 
assessed at 3 month after treatment completion. Late toxicities were 
assessed according to RTOG/EORTC scoring system. Statistical analysis 
of local control and survival were calculated using the Kaplan-Meier 
method. 
Results: A series of 23 gynecological melanoma patients were treated 
with carbonion radiotherapy between November 2004 and October 
2012. The age ranged from 51 to 80 with a median of 71. The tumor 
 
